FCM regimen: Difference between revisions

	WikiDoc Resources for FCM regimen
Articles
Most recent articles on FCM regimen Most cited articles on FCM regimen Review articles on FCM regimen Articles on FCM regimen in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on FCM regimen Images of FCM regimen Photos of FCM regimen Podcasts & MP3s on FCM regimen Videos on FCM regimen
Evidence Based Medicine
Cochrane Collaboration on FCM regimen Bandolier on FCM regimen TRIP on FCM regimen
Clinical Trials
Ongoing Trials on FCM regimen at Clinical Trials.gov Trial results on FCM regimen Clinical Trials on FCM regimen at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on FCM regimen NICE Guidance on FCM regimen NHS PRODIGY Guidance FDA on FCM regimen CDC on FCM regimen
Books
Books on FCM regimen
News
FCM regimen in the news Be alerted to news on FCM regimen News trends on FCM regimen
Commentary
Blogs on FCM regimen
Definitions
Definitions of FCM regimen
Patient Resources / Community
Patient resources on FCM regimen Discussion groups on FCM regimen Patient Handouts on FCM regimen Directions to Hospitals Treating FCM regimen Risk calculators and risk factors for FCM regimen
Healthcare Provider Resources
Symptoms of FCM regimen Causes & Risk Factors for FCM regimen Diagnostic studies for FCM regimen Treatment of FCM regimen
Continuing Medical Education (CME)
CME Programs on FCM regimen
International
FCM regimen en Espanol FCM regimen en Francais
Business
FCM regimen in the Marketplace Patents on FCM regimen
Experimental / Informatics
List of terms related to FCM regimen

VisualWikitext

Revision as of 12:54, 17 March 2015

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aparna Vuppala, M.B.B.S. [2]

Synonyms and keywords:FCMR Regimen; R-FCM Regimen; Rituximab-Fludarabine-Cyclophosphamide-Mitoxantrone Regimen

Overview

FCM regimen refers to a regimen consisting of fludarabine, cyclophosphamide, mitoxantrone used to treat indolent non-Hodgkin's lymphoma and relapsed or refractory mantle cell lymphoma.^[1]and along with rituximab for the treatment of CLL^[2]

Regimen

FFludarabine

CCyclophosphamide

MMitoxantrone

Indications

Indolent non-Hodgkin's lymphoma and relapsed or refractory mantle cell lymphoma.^[3]
CLL^[2]

References

↑ "NCI Thesaurus".
↑ ^2.0 ^2.1 Faderl S, Wierda W, O'Brien S, Ferrajoli A, Lerner S, Keating MJ (2010). "Fludarabine, cyclophosphamide, mitoxantrone plus rituximab (FCM-R) in frontline CLL <70 Years". Leuk Res. 34 (3): 284–8. doi:10.1016/j.leukres.2009.07.008. PMID 19646755.
↑ "NCI Thesaurus".

[1] "NCI Thesaurus".

[pmid19646755-2] 2.0 ^2.1 Faderl S, Wierda W, O'Brien S, Ferrajoli A, Lerner S, Keating MJ (2010). "Fludarabine, cyclophosphamide, mitoxantrone plus rituximab (FCM-R) in frontline CLL <70 Years". Leuk Res. 34 (3): 284–8. doi:10.1016/j.leukres.2009.07.008. PMID 19646755.

[3] "NCI Thesaurus".

[1]

[2]

[3]

@@ Line 6: / Line 6: @@
 ==Overview==
-{{PAGENAME}} refers to a regimen consisting of [[fludarabine]], [[cyclophosphamide]], [[mitoxantrone]] and [[rituximab]] used to treat indolent [[non-Hodgkin's lymphoma]] and relapsed or refractory [[mantle cell lymphoma]].<ref>{{Cite web | title = NCI Thesaurus | accessdate =  | url = http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C63463&ns=NCI_Thesaurus}}</ref>
+{{PAGENAME}} refers to a regimen consisting of [[fludarabine]], [[cyclophosphamide]], [[mitoxantrone]]  used to treat indolent [[non-Hodgkin's lymphoma]] and relapsed or refractory [[mantle cell lymphoma]].<ref>{{Cite web | title = NCI Thesaurus | accessdate =  | url = http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C63463&ns=NCI_Thesaurus}}</ref>and  along with [[rituximab]] for the treatment of [[CLL]]<ref name="pmid19646755">{{cite journal| author=Faderl S, Wierda W, O'Brien S, Ferrajoli A, Lerner S, Keating MJ| title=Fludarabine, cyclophosphamide, mitoxantrone plus rituximab (FCM-R) in frontline CLL <70 Years. | journal=Leuk Res | year= 2010 | volume= 34 | issue= 3 | pages= 284-8 | pmid=19646755 | doi=10.1016/j.leukres.2009.07.008 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=19646755  }} </ref>
 ==Regimen==
@@ Line 19: / Line 19: @@
 *Indolent [[non-Hodgkin's lymphoma]] and relapsed or refractory [[mantle cell lymphoma]].<ref>{{Cite web | title = NCI Thesaurus | accessdate =  | url = http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C63463&ns=NCI_Thesaurus}}</ref>
+*[[CLL]]<ref name="pmid19646755">{{cite journal| author=Faderl S, Wierda W, O'Brien S, Ferrajoli A, Lerner S, Keating MJ| title=Fludarabine, cyclophosphamide, mitoxantrone plus rituximab (FCM-R) in frontline CLL <70 Years. | journal=Leuk Res | year= 2010 | volume= 34 | issue= 3 | pages= 284-8 | pmid=19646755 | doi=10.1016/j.leukres.2009.07.008 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=19646755  }} </ref>
 ==References==